Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model
暂无分享,去创建一个
Tao Wei | Hui-Rong Qian | J. Yingling | Lei Yan | J. J. Starling | Hui-Rong Qian | Timothy P Burkholder | Lei Yan | T. Wei | Yuefeng Chen | Jonathan M Yingling | Jianyong Shou | Yuefeng Chen | Frank Lawrence | James J Starling | J. Shou | F. Lawrence | T. P. Burkholder | Frank Lawrence
[1] J. Marx. Encouraging Results for Second-Generation Antiangiogenesis Drugs , 2005, Science.
[2] Tommi S. Jaakkola,et al. Combining Location and Expression Data for Principled Discovery of Genetic Regulatory Network Models , 2001, Pacific Symposium on Biocomputing.
[3] J. Folkman,et al. CDK2 translational down-regulation during endothelial senescence. , 2005, Experimental cell research.
[4] Nir Friedman,et al. Inferring subnetworks from perturbed expression profiles , 2001, ISMB.
[5] J. Folkman. Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.
[6] Rainer Breitling,et al. Network theory to understand microarray studies of complex diseases. , 2006, Current molecular medicine.
[7] E. Jaffe,et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.
[8] J. Folkman,et al. Angiogenic factors. , 1987, Science.
[9] J. Marx. Cancer. Encouraging results for second-generation antiangiogenesis drugs. , 2005, Science.
[10] H. Wakelee,et al. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. , 2006, Drugs of today.
[11] D. Kurz,et al. Endothelial cell senescence. , 2006, Handbook of experimental pharmacology.
[12] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[13] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[14] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[15] S. Hayward,et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Folkman,et al. Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin , 2006, Science's STKE.
[17] G. Jayson,et al. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis , 2006, Expert opinion on therapeutic targets.
[18] Philip Hahnfeldt,et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer , 2007, Proceedings of the National Academy of Sciences.
[19] Patrik D'haeseleer,et al. Genetic network inference: from co-expression clustering to reverse engineering , 2000, Bioinform..
[20] J. Folkman,et al. Maintenance of G1 Checkpoint Controls in Telomerase-Immortalized Endothelial Cells , 2004, Cell cycle.
[21] P. Carmeliet,et al. Common mechanisms of nerve and blood vessel wiring , 2005, Nature.
[22] D. Bagger-sjöbäck,et al. An In Vitro Model , 1987 .
[23] Oriol Casanovas,et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.
[24] D. Jäger,et al. [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[25] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[26] Sanjay Mehrotra,et al. A model-based optimization framework for the inference of regulatory interactions using time-course DNA microarray expression data , 2007, BMC Bioinformatics.
[27] Kristian Pietras,et al. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. R. Koehler,et al. Modern Applied Statistics with S-Plus. , 1996 .
[29] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[30] E. Passegué,et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.
[31] Rakesh K Jain,et al. Molecular regulation of vessel maturation , 2003, Nature Medicine.
[32] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[33] Michael Krauthammer,et al. Probabilistic inference of molecular networks from noisy data sources , 2004, Bioinform..
[34] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[35] R. Albert,et al. The large-scale organization of metabolic networks , 2000, Nature.
[36] L. Akslen,et al. Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.
[37] M. Wirth,et al. The ratio of formation of prostacyclin/thromboxane A2 in HUVEC decreased in each subsequent passage. , 1997, Prostaglandins.
[38] P. Solenberg,et al. Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model , 2006, Arthritis research & therapy.
[39] A. Sartore-Bianchi,et al. Rationale and Clinical Results of Multi-target Treatments in Oncology , 2007, The International journal of biological markers.
[40] R. Kerbel. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. , 2005, Cancer cell.
[41] David Liu,et al. DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis , 2007, BMC Bioinformatics.
[42] Denys N. Wheatley,et al. An in vitro model of angiogenesis: Basic features , 2004, Angiogenesis.
[43] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[44] G. Soff,et al. Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.
[45] D. Pe’er,et al. Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data , 2003, Nature Genetics.